General Hospital Dr. Josip Bencevic
- Address
- lock Available on a paid plan
General Hospital Dr. Josip Bencevic
General Hospital Dr. Josip Bencevic is a clinical research center specializing in cardiovascular disease management and complex metabolic complications. The center demonstrates expertise in conducting advanced Phase 3 clinical trials focused on reducing cardiovascular risk and managing serious disease complications in high-risk patient populations.
- Atherosclerotic cardiovascular disease and lipid-modifying therapy optimization
- Acute coronary syndrome and post-myocardial infarction event prevention
- Diabetic foot infections and antimicrobial therapy evaluation
The center's research portfolio emphasizes major adverse cardiovascular event (MACE) prevention through novel therapeutic approaches, including evaluation of cholesterol-lowering agents and anticoagulation strategies. With additional focus on diabetic complications, the facility addresses the intersection of metabolic and infectious disease management, particularly in patients with moderate to severe diabetic foot infections requiring advanced antimicrobial interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Dr. Josip Bencevic
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections | Micurx Pharmaceuticals Inc. | Phase III | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.